Quick Answer
Foghorn Therapeutics Inc. reported Stockholders Equity of -$108.50 million for fiscal year 2025.
Foghorn Therapeutics Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$108.50M | -138.3% |
| 2024 | -$45.53M | +41.0% |
| 2023 | -$77.19M | -69019.6% |
| 2022 | $112.0K | -99.9% |
| 2021 | $96.87M | -33.7% |
| 2020 | $146.19M | +266.1% |
| 2019 | -$88.02M | -124.1% |
| 2018 | -$39.27M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$89.66M | -217.0% | -17.0% |
| June 30, 2025 | -$76.66M | -435.3% | -24.3% |
| March 31, 2025 | -$61.65M | +36.8% | -35.4% |
| December 31, 2024 | -$45.53M | +41.0% | -61.0% |
| September 30, 2024 | -$28.29M | +50.7% | -97.5% |
| June 30, 2024 | -$14.32M | +71.0% | +85.3% |
| March 31, 2024 | -$97.49M | -296.5% | -26.3% |
| December 31, 2023 | -$77.19M | -69019.6% | -34.5% |
- Foghorn Therapeutics Inc. showed a decrease of -138.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Foghorn Therapeutics Inc.’s stockholders equity has declined by 176.3% (from -$39.27 million to -$108.50 million).
- The most recent figure is from Foghorn Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: